SecBot SecBot
8-K ·Filed Jun 18, 2026

PFE

PFIZER INC
NEUTRAL
Impact 2/10
Horizonweeks Processed5mo ago SEC0000078003-26-000087
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

No actionable change from this filing. Guidance is unchanged, earnings risk remains on execution of existing forecasts. Monitor Pfizer's Q2 2026 earnings for any revision to FY2026 guidance or updates on the CFO search.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$25.21
T+0 close · Jun 18, 2026 · via day close
Latest settled
+9.96%
T+60 · $27.72
Vs SPY
+8.06%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 18 $25.21entry
  2. T+1 · 5mo ago −0.52%α −0.20% · $25.08
  3. T+5 · 5mo ago −6.11%α −4.44% · $23.67
  4. T+20 · 4mo ago −0.28%α −0.81% · $25.14
  5. T+60 · 2mo ago +9.96%α +8.06% · $27.72
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pfizer reaffirms full-year 2026 guidance following the CFO transition announcement on June 18, 2026. Revenue guidance remains $59.5-$62.5B and adjusted diluted EPS at $2.80-$3.00, unchanged from prior communication. This is a routine confirmation filing with no new material financial data.

Key Facts

  • FY2026 revenue guidance reaffirmed at $59.5-$62.5B
  • FY2026 adjusted diluted EPS guidance reaffirmed at $2.80-$3.00
  • CFO transition announced on June 18, 2026, prompted this reaffirmation

Financial Impact

No new financial data; previously guided revenue and EPS ranges unchanged.

revenueadj_diluted_eps

Risk Factors

  • Future earnings miss could pressure stock if revenue or EPS fall below guided ranges
  • CFO transition adds management uncertainty, potentially affecting execution

Market Snapshot

Price
$25.29
Volume
700
Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
42% bullish (36 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000078003-26-000087
Document: 0000078003-26-000087-index-headers.html0000078003-26-000087
Document: 0000078003-26-000087-index.html0000078003-26-000087
Document: 0000078003-26-000087.txt0000078003-26-000087

Track record

21 reports on PFE

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +17.28% at T+60 after the Aug 4, 2026 report. 7 of 9 went positive at some point.

Filters
  1. Nov 3, 202613d ago 8-K Neutral 2/10 Entry $30.79 Now $28.89 −6.17% settles Feb 2
  2. Nov 3, 202613d ago 8-K Bullish 6/10 Entry $30.00 Now $28.89 −3.70% settles Feb 1
  3. Oct 30, 202618d ago Court Ruling Neutral 2/10 Entry $30.67 Now $28.89 −5.80% settles Jan 29
  4. Oct 23, 202624d ago Institutional Cluster Mixed 3/10 Entry $30.03 Now $28.89 −3.80% settles Jan 21
  5. Aug 13, 202613w ago Court Ruling Neutral 1/10 Entry $26.79 to $29.23 Now $28.89 +7.84% ▲ +9.11% +12.15% vs SPY
  6. Aug 12, 202613w ago Insider Buy Bullish 5/10 Entry $26.80 to $29.39 Now $28.89 +7.80% ▲ +9.66% +15.14% vs SPY
  7. Aug 12, 202613w ago Insider Cluster Bullish 6/10 Entry $26.80 to $29.39 Now $28.89 +7.80% ▲ +9.66% +15.14% vs SPY
  8. Aug 6, 202614w ago Insider Cluster Bullish 4/10 Entry $26.20 to $30.52 Now $28.89 +10.27% ▲ +16.49% +18.16% vs SPY
  9. Aug 5, 202614w ago Insider Buy Bullish 5/10 Entry $26.20 to $30.52 Now $28.89 +10.27% ▲ +16.49% +18.16% vs SPY
  10. Aug 5, 202614w ago Insider Cluster Neutral 3/10 Entry $26.20 to $30.52 Now $28.89 +10.27% ▲ +16.49% +18.16% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens Wed (12h 41m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 18, 2026